SCHEMBL5696730

SCHEMBL5696730

CCS(=O)(=O)Cc1ccc(Cl)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAB9A P51151 1/20 0.45
MMP8 P22894 3/20 0.41
MMP12 P39900 3/20 0.41
MMP13 P45452 3/20 0.41
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.35
GSK3B P49841 1/20 0.33
PTGS2 P35354 1/20 0.33
FFAR1 O14842 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
F2 P00734 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14426994 0.87 KMT2A (0.41) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL2376899 0.82 KMT2A (0.46) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL18571275 0.79 MMP8 (0.48) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL16937291 0.79 KMT2A (0.43) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL2376897 0.78 KMT2A (0.42) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL24425795 0.74 MMP8 (0.43) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL256014 0.73
SCHEMBL16924228 0.73 MMP8 (0.50) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL18571476 0.73 MMP8 (0.42) KMT2AALDH1A1HTTSMN1; SMN2RAB9A
SCHEMBL24195865 0.72 ALDH1A1 (0.47) KMT2AALDH1A1HTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-10-04 US disclosed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US disclosed
EP-1663958-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2006-06-07 EP disclosed
WO-2005028429-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE KMT2A 4623/4885ALDH1A1 4046/4885HTT 1566/4885
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors CTSS, CTSB, CTSE KMT2A 4623/4885ALDH1A1 4046/4885HTT 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.